Skip to main content
Cell And Gene Therapy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Cell And Gene Therapy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Jul 2024 151 Pages SKU: IRTNTR74196

Market Overview at a Glance

$6.56 B
Market Opportunity
14.76%
CAGR
12.55
YoY growth 2023-2024(%)

Cell And Gene Therapy Market Size 2024-2028 

The cell and gene therapy market size is forecast to increase by USD 6.56 billion at a CAGR of 14.76% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of chronic diseases, leading to a swell in demand for innovative treatments. This includes both cell replacement and gene augmentation therapies. Strategic alliances between industry players and academic institutions are driving advancements in biomanufacturing and single-use technology, streamlining production processes and reducing costs. However, high costs and the failure rate in clinical trials remain challenges, necessitating continued investment in research and development to ensure the long-term success of this rapidly evolving industry. Apheresis technology, which enables the selective removal of specific cells from the bloodstream, is a critical component of cell culture and gene therapy, enabling the collection and processing of therapeutic cells. The clinical pipeline for cell and gene therapies is strong, with numerous potential treatments in various stages of development.

Cell And Gene Therapy Market Size

 Request Free Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • Type
    • Cell therapy
    • Gene therapy
  • Geography
    • North America
      • US
    • Europe
      • Germany
      • UK
    • Asia
      • China
      • Japan
    • Rest of World (ROW)

By Type Insights

The cell therapy segment is estimated to witness significant growth during the forecast period. Cell therapy represents a cutting-edge treatment modality where living cells are administered to patients to address various health conditions. This therapeutic approach utilizes both autologous and allogeneic cells. The market for cell therapy is experiencing significant growth due to its potential for personalized medicine. Companies are developing cell therapy products from diverse cell lines, including stem cells, to cater to the increasing demand for novel treatments for chronic diseases. The therapeutic potential of these products is driving intense research and collaboration with regulatory bodies to advance human clinical trials. The focus on pluripotent and multipotent cells is particularly noteworthy, as these cells hold immense promise for the development of innovative cell therapy solutions in fields such as hematology, ophthalmology, and neurological disorders.

Cell And Gene Therapy Market Size

Get a glance at the market share of various segments Request Free Sample

The cell therapy segment accounted for USD 2.83 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Cell And Gene Therapy Market Share by Geography

For more insights on the market share of various regions Request Free Sample

The North American region is anticipated to lead the market due to substantial investment in research and development (R&D) initiatives, particularly in the United States. With hundreds of clinical trials underway in North America, primarily in the US, to address conditions such as cancer, HIV/AIDS, neurological disorders, and cardiovascular diseases, this region holds significant potential. The prevalence of cancer in North America is high, resulting in a considerable number of deaths. This disease incidence has risen significantly in various North American countries over the years. In the field of cell and gene therapy, two distinct yet interconnected approaches are gaining traction: gene therapy and cell therapy. Gene therapy involves introducing new genetic material into cells to correct or prevent disease, while cell therapy utilizes live cells to treat or repair damaged tissues. Both approaches hold immense promise in treating various diseases, including hematological disorders and ophthalmological conditions.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

The market is experiencing significant growth due to the increasing prevalence of various diseases such as infectious diseases, oncological disorders, cardiovascular diseases, genetic disorders, and rare diseases. This market encompasses advanced targeted therapies, including gene therapy and cell therapy, which offer promising solutions for neurology, rare hematology, oncology, ophthalmology, and neurological disorders. Gene therapy involves using genes to treat or prevent diseases by introducing new genetic material into cells. Technologies like gene silencing, gene augmentation, and CRISPR are revolutionizing gene therapy by providing precise and effective methods for treating genetic disorders. Cell therapy, on the other hand, involves using living cells to treat or replace damaged cells or tissues.

This therapy is particularly useful in hematology, where cell replacement therapies are used to treat various blood disorders. Single-use technology is gaining popularity in cell therapy due to its ease of use, cost-effectiveness, and reduced risk of contamination. Biomanufacturing and apheresis are crucial components of the market. Biomanufacturing enables the large-scale production of therapeutic proteins, viral vectors, and cells, while apheresis facilitates the separation and collection of cells from the bloodstream, making it possible to isolate and purify therapeutic cells for use in various applications. Overall, the market holds immense potential for transforming healthcare and improving patient outcomes in various therapeutic areas.

Key Market  Drivers

  • Rising Prevalence of Chronic Diseases: The global burden of chronic diseases continues to increase, creating a significant unmet medical need.
  • Advancements in Biotechnology: Breakthroughs in biotechnology, such as CRISPR-Cas9 gene editing technology, have opened up new avenues for therapeutic interventions.
  • Increased Investment: Significant investments from both public and private sectors are driving the development of cell and gene therapies.

Emerging Market Trends

  • Personalized Medicine: The ability to tailor treatments to individual patients' genetic makeup is a major trend in cell and gene therapy.
  • Combination Therapies: Combining cell and gene therapies with other modalities, such as immunotherapy, is emerging as a promising approach.
  • Regulatory Landscape: Clear and efficient regulatory frameworks are essential to accelerate the development and commercialization of cell and gene therapies.

Market Challenges and Opportunities

  • High Cost of Development: The development of cell and gene therapies is a complex and expensive process, requiring substantial investments.
  • Manufacturing Challenges: Scaling up the manufacturing of cell and gene therapies to meet commercial demand remains a significant hurdle.
  • Regulatory Hurdles: Navigating the regulatory landscape can be time-consuming and costly, particularly for novel therapies.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Cell And Gene Therapy Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Biogen Inc.: The company offers cell and gene theraputic solutions named cotoretigene toliparvovec, a gene therapy for patients with X-linked retinitis pigmentosa that is associated with progressive vision loss as the light-sensing cells of the retina gradually deteriorate.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • bluebird bio Inc.
  • Bristol Myers Squibb Co.
  • Castle Creek Biosciences Inc.
  • CORESTEM Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Pharmaceuticals LLC
  • Ferring BV
  • Gilead Sciences Inc.
  • Helixmith Co. Ltd.
  • Human Stem Cells Institute
  • JCR Pharmaceticals Co. Ltd.
  • Kolon TissueGene Inc.
  • Novartis AG
  • Orchard Therapeutics Plc
  • Pfizer Inc.
  • Sibiono GeneTech Co. Ltd.
  • Vericel Corp.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

The market is experiencing significant growth due to the increasing prevalence of various diseases, including infectious diseases, oncological disorders, cardiovascular diseases, genetic disorders, and rare diseases. In the field of oncology and hematology, advanced targeted therapies such as gene therapy, cell therapy, gene editing, and T-cell receptor therapy are showing promising results in treating cancer and hematological disorders. Oligonucleotides, zinc fingers, and viral transfection are key technologies used in gene therapy. Gene therapy and cell therapy are also being explored for neurological disorders, hepatology, ophthalmology, and other chronic diseases.

Additionally, single-use technology, apheresis, and biomanufacturing are essential in the production of allogeneic cell solutions and autologous cell products. The clinical pipeline for these therapies is vital, with numerous clinical study protocols underway, and regulatory approvals being granted. Gene therapy and cell therapy hold immense potential in treating mitochondrial genetics, sickle cell anemia, rare genetic disorders, and other diseases. The market is expected to grow significantly in the coming years, driven by the increasing demand for effective treatments for various chronic and genetic conditions.

Market Scope

Report Coverage

Details

Page number

151

Base year

2023

Historic period

 2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 14.76%

Market growth 2024-2028

USD 6.56 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

12.55

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp.

Market dynamics

Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents not available.

Research Methodology

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

Interested in this report?

Get your sample now to see our research methodology and insights!

Download Now

Frequently Asked Questions

Cell And Gene Therapy market growth will increase by $ 6559.4 mn during 2024-2028.

The Cell And Gene Therapy market is expected to grow at a CAGR of 14.76% during 2024-2028.

Cell And Gene Therapy market is segmented by Type( Cell therapy, Gene therapy)

Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., Vericel Corp. are a few of the key vendors in the Cell And Gene Therapy market.

North America will register the highest growth rate of 41% among the other regions. Therefore, the Cell And Gene Therapy market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

US, Germany, UK, China, Japan

  • Increasing prevalence of chronic diseasesThere is an increasing global prevalence of various chronic diseases such as heart diseases is the driving factor this market.
  • diabetes is the driving factor this market.
  • stroke is the driving factor this market.
  • cancer is the driving factor this market.
  • obesity is the driving factor this market.
  • and arthritis. Chronic diseases present a significant burden on patients and healthcare systems. A significant population in the US has one or more chronic health conditions is the driving factor this market.
  • and one in four adults suffers from two or more chronic diseases. Unhealthy lifestyle habits such as the lack of exercise is the driving factor this market.
  • poor nutrition intake is the driving factor this market.
  • and substance abuse such as addiction to alcohol and tobacco are the major risk factors resulting in the increasing prevalence of chronic diseases. The incidence of many musculoskeletal disorders and bone injuries such as arthritis (osteoarthritis and rheumatoid arthritis) is the driving factor this market.
  • osteoporosis is the driving factor this market.
  • and serious limb trauma injuries requiring hospitalization is increasing. In the US is the driving factor this market.
  • many adults have arthritis and osteoarthritis. A significant number of people in the US and other developed countries die of heart disease every year. The prevalence of CVDs is the driving factor this market.
  • such as angina is the driving factor this market.
  • myocardial infarction (MI) is the driving factor this market.
  • stroke is the driving factor this market.
  • heart failure is the driving factor this market.
  • venous thromboembolism is the driving factor this market.
  • and heart arrhythmia is the driving factor this market.
  • is also increasing. CVDs account for a major share of total deaths occurring in the EU each year. Most chronic diseases may result in tissue or organ damage. The vast majority of treatments available for chronic diseases are palliative. In contrast is the driving factor this market.
  • other treatment options can delay disease progression and the onset of complications associated with the underlying illness. Regenerative medicine opens the possibility of overcoming previously untreatable diseases using new treatment methods such as processed cells for reconstructing tissues. It has the unique capability of altering the fundamental mechanisms of diseases. It also helps in reducing healthcare costs by eliminating the need for long-term hospitalization or drug regimes. Similarly is the driving factor this market.
  • the number of cancer patients is rapidly increasing across the world. According to the Centers for Disease Control and Prevention (CDC ) is the driving factor this market.
  • in the US is the driving factor this market.
  • in 2019 is the driving factor this market.
  • 1 is the driving factor this market.
  • 752 is the driving factor this market.
  • 735 new cancer cases were reported and 599 is the driving factor this market.
  • 589 people died of cancer. For every 100 is the driving factor this market.
  • 000 people is the driving factor this market.
  • 439 new cancer cases were reported and 146 people died of cancer in 2019 . A potentially helpful cancer treatment method is gene therapy is the driving factor this market.
  • which involves replacing a dysfunctional gene with a functional is the driving factor this market.
  • healthy copy of that gene. This is a potentially beneficial cancer treatment approach compared with chemotherapy is the driving factor this market.
  • which sometimes lacks selectivity and can result in non-specific damage. A novel therapeutic approach called gene transfer involves the insertion of new genes into a cancerous cell or the surrounding tissue to cause cell death or reduce the growth of cancer. A wide variety of genes and vectors are being employed in clinical trials with positive results because of the versatility of this therapy method. Thus is the driving factor this market.
  • all these factors will lead to the increased adoption of cell and gene therapies for the treatment of chronic diseases is the driving factor this market.
  • which is the driving factor this market.
  • in turn is the driving factor this market.
  • is expected to drive the growth of the global cell and gene therapy market during the forecast period.   is the driving factor this market.

The Cell And Gene Therapy market vendors should focus on grabbing business opportunities from the Cell therapy segment as it accounted for the largest market share in the base year.